CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease

David J. Friedman(Broad Institute), Simon C. Robson(Beth Israel Deaconess Medical Center), Keiichi Enjyoji(Beth Israel Deaconess Hospital), Yousif I. A-Rahim(University of Hawaii System), Beat Künzli(Beth Israel Deaconess Medical Center), Eva Csizmadia(Beth Israel Deaconess Medical Center), Pascal O. Berberat(Technical University of Munich), Helmut Frieß(TUM Klinikum), Jean Sévigny(Université Laval)
Proceedings of the National Academy of Sciences
September 28, 2009
Cited by 284


Related Papers